Understanding the disparity: predictors of virologic failure in women using highly active antiretroviral therapy vary by race and/or ethnicity.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Author
McFall, Allison MDowdy, David W
Zelaya, Carla E
Murphy, Kerry
Wilson, Tracey E
Young, Mary A
Gandhi, Monica
Cohen, Mardge H
Golub, Elizabeth T
Althoff, Keri N
Journal title
Journal of acquired immune deficiency syndromes (1999)Date Published
2013-11-01Publication Volume
64Publication Issue
3Publication Begin page
289Publication End page
98
Metadata
Show full item recordAbstract
Background: Stark racial/ethnic disparities in health outcomes exist among those living with HIV in the United States. One of 3 primary goals of the National HIV/AIDS Strategy is to reduce HIV-related disparities and health inequities.Methods: Using data from HIV-infected women participating in the Women's Interagency HIV Study from April 2006 to March 2011, we measured virologic failure (HIV RNA >200 copies/mL) after suppression (HIV RNA < 80 copies/mL) on highly active antiretroviral therapy. We identified predictors of virologic failure using discrete time survival analysis and calculated racial/ethnic-specific population-attributable fractions (PAFs).
Results: Of 887 eligible women, 408 (46%) experienced virologic failure during the study period. Hispanic and white women had significantly lower hazards of virologic failure than African American women [Hispanic hazard ratio, (HR) = 0.8, 95% confidence interval: (0.6 to 0.9); white HR = 0.7 (0.5 to 0.9)]. The PAF of virologic failure associated with low income was higher in Hispanic [adjusted hazard ratios (aHR) = 2.2 (0.7 to 6.5), PAF = 49%] and African American women [aHR = 1.8 (1.1 to 3.2), PAF = 38%] than among white women [aHR = 1.4 (0.6 to 3.4), PAF = 16%]. Lack of health insurance compared with public health insurance was associated with virologic failure only among Hispanic [aHR = 2.0 (0.9 to 4.6), PAF = 22%] and white women [aHR = 1.9 (0.7 to 5.1), PAF = 13%]. By contrast, depressive symptoms were associated with virologic failure only among African-American women [aHR = 1.6 (1.2 to 2.2), PAF = 17%].
Conclusions: In this population of treated HIV-infected women, virologic failure was common, and correlates of virologic failure varied by race/ethnicity. Strategies to reduce disparities in HIV treatment outcomes by race/ethnicity should address racial/ethnic-specific barriers including depression and low income to sustain virologic suppression.
Citation
McFall AM, Dowdy DW, Zelaya CE, Murphy K, Wilson TE, Young MA, Gandhi M, Cohen MH, Golub ET, Althoff KN; Women's Interagency HIV Study. Understanding the disparity: predictors of virologic failure in women using highly active antiretroviral therapy vary by race and/or ethnicity. J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):289-98. doi: 10.1097/QAI.0b013e3182a095e9. PMID: 23797695; PMCID: PMC3816935.DOI
10.1097/QAI.0b013e3182a095e9ae974a485f413a2113503eed53cd6c53
10.1097/QAI.0b013e3182a095e9
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
Related articles
- Understanding Cross-Sectional Racial, Ethnic, and Gender Disparities in Antiretroviral Use and Viral Suppression Among HIV Patients in the United States.
- Authors: Beer L, Mattson CL, Bradley H, Skarbinski J, Medical Monitoring Project
- Issue date: 2016 Mar
- Disparities in Viral Suppression and Medication Adherence among Women in the USA, 2011-2016.
- Authors: Geter A, Sutton MY, Armon C, Buchacz K, HIV Outpatient Study Investigators
- Issue date: 2019 Nov
- Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005.
- Authors: Lillie-Blanton M, Stone VE, Snow Jones A, Levi J, Golub ET, Cohen MH, Hessol NA, Wilson TE
- Issue date: 2010 Aug
- Perceived discrimination is associated with reduced breast and cervical cancer screening: the Study of Women's Health Across the Nation (SWAN).
- Authors: Jacobs EA, Rathouz PJ, Karavolos K, Everson-Rose SA, Janssen I, Kravitz HM, Lewis TT, Powell LH
- Issue date: 2014 Feb
- Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.
- Authors: Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, Fischl MA, Schackman BR, Riddler SA, Gulick RM
- Issue date: 2013 Dec